Histomorphometric analysis of osteoclastic bone resorption in metastatic bone disease from various primary malignomas
- 1 January 1986
- journal article
- research article
- Published by Springer Nature in Virchows Archiv
- Vol. 409 (6) , 817-828
- https://doi.org/10.1007/bf00710766
Abstract
The present study deals with qualitative und quantitative analysis of osteoclastic bone resorption in metastatic bone disease. 267 cases were examined histomorphologically and divided into three developmental stages. In the first ‘phase of early appearance’ no bone resorption takes place. The stimulation of osteoclastic resorption in the surroundings of tumour tissue is typical in the second ‘phase of interaction’. Pressure atrophy, aseptic necrosis and osteolysis by the tumour cells themselves are other mechanisms of bone destruction in the last ‘phase of carcinomatosis’. Because osteoclasts are exclusively responsible for the loss of bone tissue in the ‘phase of interaction’, this stage is suited for precise quantitative analysis of osteoclastic resorption. 24 pure osteolytic secondary bone tumours of various primary lesions were examined histomorphometrically. The numerical values were compared with each other and with standard values of healthy individuals. In contrast with normal bone tissue the fractional resorption surfaces und osteoclast indices increase in metastases. Activated osteoclasts are larger and have more nuclei. The numbers of osteoclast index and nuclei per osteoclast are significantly higher in renal than in breast carcinoma. Osteoclasts can be activated in distances of more than 500 µm from tumour tissue. The mean stimulation distance in metastasis from squamous cell carcinoma is markedly higher than in secondary bone tumours of breast carcinoma. Several osteoclast activating substances and divers mechanisms of stimulation might be responsible for different numerical values of morphometric parameters in metastases from various primary malignancies.Keywords
This publication has 29 references indexed in Scilit:
- Absence of Parathyroid Hormone Messenger RNA in Nonparathyroid Tumors Associated with HypercalcemiaNew England Journal of Medicine, 1983
- The effect of parathyroid hormone, 1,25‐dihydroxycholecalciferol and prostaglandins on the cytoplasmic activity of isolated osteoclastsxsThe Journal of Pathology, 1982
- New Knowledge on the Origin, Function and Fate of OsteoclastsPublished by Wolters Kluwer Health ,1981
- The effect of prostaglandin synthesis inhibitors and diphosphonates on tumour-mediated osteolysisBritish Journal of Surgery, 1980
- Epidermal growth factor stimulates prostaglandin production and bone resorption in cultured mouse calvariaBiochemical and Biophysical Research Communications, 1978
- Big and Little Forms of Osteoclast Activating FactorJournal of Clinical Investigation, 1977
- Relationship of bone destruction in skeletal metastases to osteoclast activation and prostaglandinsNature, 1976
- BREAST-CANCER OSTEOLYSIS, BONE METASTASES, AND ANTI-OSTEOLYTIC EFFECT OF ASPIRINThe Lancet, 1976
- Effect of osteoclast activating factor from human leukocytes on bone metabolism.Journal of Clinical Investigation, 1975
- TREATMENT OF OSTEOLYTIC MYELOMATOSIS WITH MITHRAMYCINThe Lancet, 1975